2026-12843NoticeWallet

Government Selling Special Human Cell Line for Virus Research

Published Date: 6/25/2026

Notice

Summary

The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

C8166-45 Available for Licensing

The National Cancer Institute is offering the human T‑cell line C8166-45 (NIH Reference Number E-272-2007) for non-exclusive licensing. The product is fully developed, listed as Research Material/Tool, and Patents: N/A; inquiries are directed to Diptadip Dattaroy, Ph.D., phone 240-276-7092 (Dated: June 23, 2026).

Tool for Gene Therapy Safety Testing

The C8166-45 cell line is highly permissive to HIV-1 infection and is characterized as suitable for replication-competent lentiviral (RCL) assays to assess safety of gene therapy products such as lentiviral vectors. NCI highlights its use for studying HTLV-1 and HIV biology and for testing RCL assay sensitivity (NIH Reference Number E-272-2007).

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
6/25/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register